Skip to main content
Equibles
PGEN logo

PGEN · Precigen, Inc. · Metrics

Track PGEN — free

Use PGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.22 -0.17 (-2.66%)
Russell 2000 member Rebalance outlook locked
Customer concentration — key customers 49.9% of revenue

Key customers — 49.9% of revenue (the three months ended March 31, 2025)

“For the three months ended March 31, 2025, four customers accounted for 49.9% of total condensed consolidated revenues.”
View the 10-Q filed May 13, 2026
Market Cap
$2.29B
Shares
358.04M
Volume · Oct 23 4.28M Avg daily vol (3M) 5.2M

PGEN metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.19
Market cap
$2.29B

Price action

20 metrics
Price change (1W)
-11.2%
Price change (30D)
-19.0%
Price change (3M)
+15.3%
Price change (6M)
+61.4%
Price change (YTD)
+52.9%
Price change (1Y)
+63.4%
Trailing year
Price change (5Y)
+39.2%
52-week high
$8.56
52-week low
$3.10
Change from 52-week high
-25.4%
Change from 52-week low
+106.1%
Annualized volatility
79.2%
Annualized volatility (3M)
62.3%
Beta
1.5
RSI (14D)
36.8
Price vs SMA 50
-12.1%
Price vs SMA 200
+22.6%
Avg volume (3M)
5.18M
Relative volume
1.2
Average dollar volume
$36.86M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
358.04M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
28.2×
reciprocal yield 3.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
27.6×
reciprocal yield 3.6%
P / book
54.2
reciprocal yield 1.8%
FCF yield
-4.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-6.7%

Historical valuation

8 metrics
P / E historical average (3Y)
9.3×
reciprocal yield 10.7%
P / E historical average (5Y)
9.3×
reciprocal yield 10.7%
EV / revenue historical average (3Y)
25.8×
reciprocal yield 3.9%
EV / revenue historical average (5Y)
13.7×
reciprocal yield 7.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
—
Operating margin
-46.1%
Trailing 12 months
Net margin
-2,588.2%
Gross profit (TTM)
$168.41M
Operating profit (TTM)
−$39.50M
Net income (TTM)
−$157.71M
Trailing 12 months
Diluted EPS (TTM)
$-1.07
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$1.36
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.06

Growth

11 metrics
Revenue growth YoY
+6,322.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$85.72M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+39.6%
Year over year · more shares
Revenue CAGR (3Y)
-28.9%
Revenue CAGR (5Y)
-21.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-361.9%
Return on assets
-92.6%
Debt / equity
2.2
Current ratio
4.6
EBITDA (TTM)
−$35.36M
Free cash flow (TTM)
−$115.22M
Quick ratio
4.6
Interest coverage
-4.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$55.67M
Latest balance sheet
Cash & equivalents
$16.33M
Total assets
$170.30M
Total debt
$93.88M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$114.17M
Capital expenditures (TTM)
$1.06M
R&D (TTM)
$32.29M
SG&A (TTM)
$84.93M
Stock compensation (TTM)
$13.14M
R&D / revenue
37.7%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
211
13F filer change QoQ
+5
Institutional ownership
40.7%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
15.1%
Private-fund adviser ownership
12.3%
Active holders' share change QoQ
+1.4%
Holder tenure
13.1
Price vs estimated holder cost
+52.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.2%

Short interest

3 metrics
Short interest
13.3%
Latest settlement · 7.4 days to cover
Days to cover
7.4d
Short-squeeze score
68 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.37M
Insider-sentiment score
38 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1356090 CUSIP 74017N105 13F (30d) 30 filings 30 filers Visit website Investor relations